Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer

被引：0
|
作者：
Orlando, Laura [1 ]
Cardillo, Anna [1 ]
Ghisini, Raffaella [1 ]
Rocca, Andrea [1 ]
Balduzzi, Alessandra [1 ]
Torrisi, Rosalba [1 ]
Peruzzotti, Giulia [1 ]
Goldhirsch, Aron [1 ]
Pietri, Elisabetta [1 ]
Colleoni, Marco [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：76 / 76
页数：1
相关论文
共 50 条
  • [31] The antitumor immune response in HER-2 positive, metastatic breast cancer patients
    Juranic, ZD
    Neskovic-Konstantinovic, Z
    Stanojkovic, TP
    Zizak, Z
    Srdic, T
    Stanojevic-Bakic, N
    Milosevic, D
    Jovanovic, D
    JOURNAL OF TRANSLATIONAL MEDICINE, 2005, 3 (1)
  • [32] Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients
    Bighin, Claudia
    Pronzato, Paolo
    Del Mastro, Lucia
    FUTURE ONCOLOGY, 2013, 9 (07) : 955 - 957
  • [33] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Masataka Yoshimoto
    Shintaro Takao
    Masaru Hirata
    Yasushi Okamoto
    Sumio Yamashita
    Yoshihiro Kawaguchi
    Makoto Takami
    Hidemi Furusawa
    Satoshi Morita
    Chigusa Abe
    Junichi Sakamoto
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 331 - 338
  • [34] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
    Yoshimoto, Masataka
    Takao, Shintaro
    Hirata, Masaru
    Okamoto, Yasushi
    Yamashita, Sumio
    Kawaguchi, Yoshihiro
    Takami, Makoto
    Furusawa, Hidemi
    Morita, Satoshi
    Abe, Chigusa
    Sakamoto, Junichi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 331 - 338
  • [35] Metronomic cyclophosphamide and capecitabine combined with lapatinib in heavily pretreated metastatic breast cancer (MBC) HER2-positive patients.
    Cagossi, Katia
    Lazzaretti, Maria Grazia
    Ferrari, Alessia
    Razzini, Giorgia
    Leporati, Meri
    Silvestri, Rosangela
    Iadanza, Manlio
    Iop, Aldo
    Artioli, Fabrizio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [37] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [38] Evaluation of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab
    Bachir, B.
    Anouti, S.
    Jaoude, J. Abi
    Kayali, M.
    Tfayli, A.
    De Azambuja, E.
    Poortmans, P.
    Zeidan, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S7 - S7
  • [39] Trastuzumab therapy in HER2-positive, metastatic breast cancer
    Smith, A. D.
    Guilbert, K.
    Lister, D.
    Streilein, S.
    Bourrier, V. C.
    Lozar, B.
    Navaratnam, S.
    Harding, G. A.
    Pitz, M. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] HER-2-positive metastatic breast cancer: trastuzumab and beyond
    Metro, Giulio
    Mottolese, Marcella
    Fabi, Alessandra
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (15) : 2583 - 2601
12345